Zealand Pharma As Stock Performance
| ZLDPF Stock | USD 104.05 2.44 2.40% |
The firm maintains a market beta of 0.0766, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Zealand Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Zealand Pharma is expected to be smaller as well. At this point, Zealand Pharma AS has a negative expected return of -0.25%. Please make sure to check out Zealand Pharma's jensen alpha, as well as the relationship between the skewness and day median price , to decide if Zealand Pharma AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Zealand Pharma AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite abnormal performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 960.2 M | |
| Total Cashflows From Investing Activities | -18.1 M |
Zealand |
Zealand Pharma Relative Risk vs. Return Landscape
If you would invest 12,600 in Zealand Pharma AS on September 2, 2024 and sell it today you would lose (2,195) from holding Zealand Pharma AS or give up 17.42% of portfolio value over 90 days. Zealand Pharma AS is currently producing negative expected returns and takes up 3.061% volatility of returns over 90 trading days. Put another way, 27% of traded pink sheets are less volatile than Zealand, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Zealand Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zealand Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Zealand Pharma AS, and traders can use it to determine the average amount a Zealand Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0807
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZLDPF |
Estimated Market Risk
| 3.06 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Zealand Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zealand Pharma by adding Zealand Pharma to a well-diversified portfolio.
Zealand Pharma Fundamentals Growth
Zealand Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Zealand Pharma, and Zealand Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zealand Pink Sheet performance.
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 1.45 B | |||
| Shares Outstanding | 51.28 M | |||
| Price To Earning | 4.03 X | |||
| Price To Book | 27.79 X | |||
| Price To Sales | 5.19 X | |||
| Revenue | 292.57 M | |||
| EBITDA | (982.6 M) | |||
| Cash And Equivalents | 864.44 M | |||
| Cash Per Share | 18.68 X | |||
| Total Debt | 647.91 M | |||
| Debt To Equity | 0.96 % | |||
| Book Value Per Share | 7.91 X | |||
| Cash Flow From Operations | (1.21 B) | |||
| Earnings Per Share | (3.26) X | |||
| Total Asset | 2.07 B | |||
| Retained Earnings | (1.24 B) | |||
| Current Asset | 408 M | |||
| Current Liabilities | 52 M | |||
About Zealand Pharma Performance
By analyzing Zealand Pharma's fundamental ratios, stakeholders can gain valuable insights into Zealand Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zealand Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zealand Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Zealand Pharma AS, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 237 people.Things to note about Zealand Pharma AS performance evaluation
Checking the ongoing alerts about Zealand Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Zealand Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zealand Pharma AS generated a negative expected return over the last 90 days | |
| Zealand Pharma AS has high historical volatility and very poor performance | |
| The company reported the revenue of 292.57 M. Net Loss for the year was (1.02 B) with profit before overhead, payroll, taxes, and interest of 173.75 M. | |
| Zealand Pharma AS has accumulated about 864.44 M in cash with (1.21 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.68. | |
| Roughly 56.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Zealand Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zealand Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Zealand Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zealand Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zealand Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zealand Pharma's pink sheet. These opinions can provide insight into Zealand Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Zealand Pink Sheet analysis
When running Zealand Pharma's price analysis, check to measure Zealand Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zealand Pharma is operating at the current time. Most of Zealand Pharma's value examination focuses on studying past and present price action to predict the probability of Zealand Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zealand Pharma's price. Additionally, you may evaluate how the addition of Zealand Pharma to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |